(Albany, US) DelveInsight has launched a new report Genital Herpes Market
DelveInsight’s Genital Herpes Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Genital Herpes, historical and forecasted epidemiology as well as the Genital Herpes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Genital Herpes market report provides current treatment practices, emerging drugs, Genital Herpes market share of the individual therapies, current and forecasted Genital Herpes market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Genital Herpes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Genital Herpes (GH), is a common sexually transmitted disease caused due to two viruses namely: herpes simplex virus 1 (HSV1) and herpes simplex virus 2 (HSV2) characterized by lifelong infection and periodic reactivation with no cure. Viruses penetrate the body through mucous membranes which line the openings of nose, mouth and genitalia.HSV1, HSV2 are found in body fluids of infected person. The appearance of a blister is known as outbreak. First outbreak will appear as early as two days after the virus has been contracted, or as late as 30 days afterward. A visible outbreak consists of single or clustered vesicles on the genitalia, perineum, buttocks, upper thighs, or perianal areas that ulcerate before resolving. Symptoms of primary infection may include malaise, fever, or localized lymphadenopathy. Subsequent outbreaks, caused by reactivation of latent virus, are usually milder. Although HSV-1 and HSV-2 cannot be distinguished visually, they exhibit differences in behavior that may affect management. Patients with HSV-2 have a higher risk of acquiring human immunodeficiency virus (HIV) infection. Genital Herpes is more prevalent among the females as compared to the males
Request for free sample page: - https://www.delveinsight.com/sample-request/genital-herpes-market
Genital Herpes Treatment
The DelveInsight Genital Herpes market report gives a thorough understanding of the Genital Herpes by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. This segment of the report covers the detailed diagnostic methods or tests for Genital Herpes. It covers the details of conventional and current medical therapies available in the Genital Herpes market for the treatment of the condition. It also provides Genital Herpes treatment algorithms and guidelines in the United States, Europe, and Japan.
Genital Herpes Market
As per DelveInsight’s estimates, the therapeutic market of Genital Herpes in seven major markets was USD 899 million in 2017. The United States accounted for the largest market size of Genital Herpes, in comparison to EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan. Among the EU5 countries, Germany had the highest market size with USD 119 million in 2017, while the UK had the lowest market size of Genital Herpes with USD 55 million in 2017. Genital Herpes is a Sexually Transmitted Disease (STD) which is caused by the Herpes Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 (HSV-2). Genital Herpes can be transmitted through vaginal, anal,
or oral sex with someone who is suffering from Genital Herpes. Genital Herpes leads to the development of sores on the genital or rectal area, buttocks, and thighs. Treatment should be based on the patient's disease profile, sexual practices, and psychosocial needs. Episodic and suppressive treatment of herpes is aimed at reducing the severity, duration, and recurrence of symptoms, and at preventing transmission to uninfected partners. Suppressive treatment may be intermittent or continuous. There are currently three FDA approved anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States. All drugs are acyclic nucleoside analogs and their specific antiviral activity is based on one key enzyme of HSV-1 and HSV-2, the thymidine kinase that converts the antiviral compounds to their monophosphates. Catalyzed by cellular enzymes, the monophosphates of nucleoside analogs are further phosphorylated to diphosphates and the active triphosphates that inhibit and fix the viral DNA polymerases, an essential enzyme for HSV-1 and HSV-2 replication. However these drugs has shown to be effective in managing the Genital Herpes frequent recurrence and healing of lesions but they are not fully potent in clearing the underline HSV infection. Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of anti-virals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Herpes simplex virus (HSV) causes an incurable viral infection that affects millions of people worldwide. The virus spreads through close person-to-person contact, breeching the mucocutaneous barrier by direct mucosal penetration or through micro abrasions in the skin.
Genital Herpes Report Scope
- The report covers the descriptive overview of Genital Herpes, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Genital Herpes epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Genital Herpes are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Genital Herpes market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Genital Herpes market
Request for free sample page: - https://www.delveinsight.com/sample-request/genital-herpes-market
Table of content
1. Key Insights
2. Executive Summary of Genital Herpes
3. Competitive Intelligence Analysis for Genital Herpes
4. Genital Herpes: Market Overview at a Glance
5. Genital Herpes: Disease Background and Overview
6. Patient Journey
7. Genital Herpes Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Genital Herpes Treatment
11. Marketed Products
12. Emerging Therapies
13. Genital Herpes: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Genital Herpes
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Genital Herpes market
- To understand the future market competition in the Genital Herpes market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes market
- To understand the future market competition in the Genital Herpes market
Related Reports
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
